Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17940865 | 0.97 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL26730987 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL13212401 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL17941049 | 0.84 | KDM4E (0.55) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL11835979 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL31380418 | 0.83 | HDAC3 (0.46) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL31380434 | 0.83 | HDAC3 (0.46) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL22422975 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL9760037 | 0.80 | TSHR (0.56) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E | |
| SCHEMBL7313338 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1ACHETSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | SMN1; SMN2 1897/4885ALDH1A1 283/4885ACHE 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.